Journal
CLINICAL CARDIOLOGY
Volume 41, Issue 1, Pages 159-165Publisher
WILEY
DOI: 10.1002/clc.22862
Keywords
Low-Density Lipoprotein Cholesterol; Nutraceuticals; SAMS; Statin Myopathy
Categories
Ask authors/readers for more resources
There is considerable evidence for the role of low-density lipoprotein cholesterol (LDL-C) in the development of atherosclerotic cardiovascular disease. Although statin therapy remains the most frequency prescribed medication to reduce LDL-C and lower risk of cardiovascular disease, a considerable number of patients develop muscle-related side affects. This review summarizes recent literature supporting the role of nutraceuticals as LDL-C-lowering therapy in statin-intolerant patients, with evidence from our own clinical practices.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available